Dr. Shetty joined the faculty in 1997 as an Assistant professor in the Department of Medicine, UT Health Center and is currently serving as a Professor of Cellular and Molecular Biology. For about twenty-nine years, Dr. Shetty’s research is focused mainly on molecular mechanisms of posttranscriptional regulation of gene expression, tumor suppressor protein, p53-uPA fibrinolytic system cross-talk, and caveolin-1 (Cav1) and p53 role in lung epithelial injury, fibroproliferation and remodeling.

His major research interests are chronic lung diseases such as pulmonary fibrosis (PF) and chronic obstructive pulmonary disease (COPD). Development and testing of Cav1-derived peptide CSP7 intervention to reduce airway and alveolar epithelial injury and fibrotic lung remodeling. This work has been continuously supported by NIH (NHLBI and NIEHS), FAMRI, AHA and DoD for the twenty-five years. Using a bench-to-bedside approach, we sought to translate and commercialize CSP7 our lab’s basic research to novel clinical therapy in IPF, through a start-up biotechnology company called Lung Therapeutics, Inc. (LTI) formed by UT system and UTHSCT. A phase 1 (NCT04233814) clinical trial of CSP7 (also called LTI-03) was sponsored and recently completed LTI in preparation for eventual treatment of patients with IPF. A follow-up phase-II international clinical trial of a dry powder formulation of CSP7 in patients with IPF will be initiated in July 2022. While LTI is commercializing CSP7 for treatment of IPF, we will continue our work focusing on translational science to explore and elucidate novel mechanism(s) by which the protective effects of CSP7 and other interventions against PF and COPD are achieved, potentially enabling even better targeted interventional possibilities.

Previous Employment

Instructor of Medicine, Department of Medicine, University of Texas Health Center, Tyler, TX (1995-1996).

Assistant Professor of Medicine, Department of Medicine, University of Texas Health Center, Tyler, TX (1997-1999).

Associate Professor of Medicine, Department of Medicine, University of Texas Health Center, Tyler, TX (1999-2004).

Professor of Medicine, Department of Medicine, University of Texas Health Center, Tyler, TX (2004-2015).

Professor of Cellular and Molecular Biology, Department of Cellular and Molecular Biology, University of Texas Health Science Center, Tyler, TX.

Education and Training

Postdoctoral Res Associate/Instructor, Department of Medicine, University of Texas Health Center, Tyler, TX

Postdoctoral Research Associate, Molecular Biology, Center for Cellular Mol Biol, India

PhD, Biosciences, Mangalore University, Mangalore, India

MS Biosciences Mangalore University, Mangalore, India

BS Mangalore University, Mangalore, India

Courses Taught

BIOT 5221 Protein & Nucleic Acids

BIOT 6311 RNA Structure, Function & Biotechnology

Research Interests

COPD, lung fibrosis, lung epithelial biology and airway and alveolar remodeling. Gene expression, posttranscriptional regulation, peptide, protein and antibody drug development for treatment of COPD and idiopathic pulmonary fibrosis (IPF)/interstitial lung diseases. Epigenetic control of lung injury and lung fibrosis, drug delivery, pharmacokinetics and toxicology of peptide, protein and antibody and therapeutics.

Recent Publications from a total of 99:

1. Shalini V, Fan L, Tang H, Konduru NV and Shetty S (2022) Caveolin-1 scaffolding domain peptide abrogates autophagy dysregulation in pulmonary fibrosis. Scientific Reports (in press).

2. Komatsu, S, Shetty RS, Fan L, Tsukasaki Y, Shetty S and Ikebe, M (2022) Caveolin-1 derived peptide reduces ER Stress and enhances gelatinolytic activity in IPF fibroblasts. Int J Mol. Sci, 23(6): 3316. doi: 10.3390/ijms23063316 PMCID: PMC8950460

3. Hogan TB, Tiwari N, Nagaraja MR, Shetty SK, Fan L, Shetty RS, Bhandary YS and Shetty S (2022). Caveolin-1 peptide regulates p53-microRNA-34a feedback in fibrotic lung fibroblasts. iScience 25(4):104022. doi:10.1016/ j.isci.2022. 104022 PMCID: PMC8938287.

4. Hao Q, Shetty S, Tucker TA, Idell S and Tang H (2022) Interferon- Preferentially Promotes Necroptosis of Lung Epithelial Cells by Upregulating MLKL. Cells. 11(3): 563 doi: 10.3390/cells11030563 PMCID: PMC8833897.

5. Gopu V, Liang Fan, Shetty RS, Nagaraja MR and Shetty S (2020) Caveolin-1 scaffolding domain peptide regulates glucose metabolism in lung fibrosis. JCI Insight 5(19): e137969. doi: 10.1172/jci.insight.137969. PMCID: PMC7566714.

6. Marudamuthu AS, Bhandary, YP, Gopu V, Fan L, Radhakrishnan V., Mackenzie, B, Maier, E, Shetty SK, Nagaraja MR, Gopu, V, Tiwari N, Zhang Y, Watts AB, Williams RO, Criner GJ, Marchetti N, Bolla S, Idell S, and Shetty S (2019) Caveolin-1–derived peptide limits development of pulmonary fibrosis. Sci Transl Med 11, eaat2848.

7. Nagaraja MR, Tiwari N, Shetty SK, Marudamuthu AS, Fan L, Ostrom RS, Fu J, Gopu V, Radhakrishnan V, Idell S, and Shetty S (2018) p53 expression in lung fibroblasts is linked to mitigation of fibrotic lung remodeling. Am J Pathol 188: 2207-2222. https://doi.org/10.1016/ J.ajpath. 2018.07.005

8. Hengsawas SS, Florova G, Komissarov AA, Shetty S, Idell S, Williams RO (2017) Formulation for a Novel Inhaled Peptide Therapeutic for Idiopathic Pulmonary Fibrosis. Drug Dev Ind Pharm. 23:1-54. PMID: 28835128.

9. Shetty SK, Tiwari N, Marudamuthu AS, Puthusseri B, Bhandary YP, Idell S, Fu J, Levin J, and Shetty S (2017) p53 and microRNA-34a feedback promotes lung epithelial injury and remodeling. Am J Pathol 187:1016-1034. PMID: 28273432.

10. Puthusseri B, Marudamuthu A, Tiwari N, Fu J, Idell S and Shetty S. Induction of p53 and downstream changes by loss of surfactant protein-C expression in alveolar epithelial cells during lung injury. Am J Physiol Lung Cell Mol Physiol, 312(6):L783-L796312, 2017.